Alnylam Pharmaceuticals Inc. (ALNY)
Alnylam Hit Hard As Investors Forced To Revise Future Profit Expectations
Alnylam Pharmaceuticals has declined nearly 40% from its all-time high, pressured by near-term TTR market dynamics and longer-term profitability concerns. The TTR business will likely remain "noisy" in the first half of 2026, but Amvuttra continues to gain share, and management guidance for 2026 was above expectations. Management alarmed the Street earlier this year with long-term spending guidance that was considerably higher than expected; management continues to prioritize R&D to realize the company's full long-term potential.
ALNY Q4 Earnings Beat, Sales Miss Despite Y/Y Growth, Stock Down
Alnylam tops Q4 earnings estimates but misses on sales despite 85% revenue growth, as booming Amvuttra demand fails to lift shares.
Alnylam Pharmaceuticals, Inc. (ALNY) Q4 2025 Earnings Call Transcript
Alnylam Pharmaceuticals, Inc. (ALNY) Q4 2025 Earnings Call Transcript
Here's What Key Metrics Tell Us About Alnylam (ALNY) Q4 Earnings
Although the revenue and EPS for Alnylam (ALNY) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Alnylam Pharmaceuticals (ALNY) Surpasses Q4 Earnings Estimates
Alnylam Pharmaceuticals (ALNY) came out with quarterly earnings of $1.25 per share, beating the Zacks Consensus Estimate of $1.16 per share. This compares to earnings of $0.06 per share a year ago.
Countdown to Alnylam (ALNY) Q4 Earnings: A Look at Estimates Beyond Revenue and EPS
Besides Wall Street's top-and-bottom-line estimates for Alnylam (ALNY), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2025.
Alnylam Pharmaceuticals (ALNY) Earnings Expected to Grow: Should You Buy?
Alnylam (ALNY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Alnylam Pharmaceuticals, Inc. (ALNY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Alnylam Pharmaceuticals, Inc. (ALNY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Is Alnylam Pharmaceuticals a Millionaire Maker?
Alnylam has been a big winner for investors since its IPO in 2004. The drugmaker's future looks promising.
American Century Ultra Fund Q3 2025 Contributors/Detractors And Notable Trades
Google's parent company received a relatively benign antitrust ruling that would not force Alphabet to sell its Chrome browser or Android operating system. Chipotle Mexican Grill reported mixed quarterly results as a result of tough year-over-year comparisons and an uncertain macroeconomic environment. We initiated a position in Oracle, which is highly levered to the ongoing artificial intelligence infrastructure build-out.
Alnylam Pharmaceuticals, Inc. (ALNY) Presents at Jefferies London Healthcare Conference 2025 Transcript
Alnylam Pharmaceuticals, Inc. ( ALNY ) Jefferies London Healthcare Conference 2025 November 19, 2025 6:30 AM EST Company Participants Yvonne Greenstreet - CEO & Director Tolga Tanguler - Executive VP & Chief Commercial Officer Conference Call Participants Maurice Raycroft - Jefferies LLC, Research Division Presentation Maurice Raycroft Jefferies LLC, Research Division Hi, everyone. My name is Maurice Raycroft, and I'm one of the Biotech Analysts at Jefferies.
Is Alnylam Pharmaceuticals (ALNY) Stock Outpacing Its Medical Peers This Year?
Here is how Alnylam Pharmaceuticals (ALNY) and Collegium Pharmaceutical (COLL) have performed compared to their sector so far this year.
